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Available online 22 February 2017Background: Several studies have suggested circulating microRNAs (miRs) are associated with heart failure, but
these studies were small, and limited to single miR measurements.
We examined 7 miRs which were previously linked to heart failure, and tested whether their temporal expres-
sion level predicts prognosis in a prospective cohort of chronic heart failure (CHF) patients.
Methods and results: In 2011–2013, 263 CHF patients were included. At inclusion and subsequently every
3months, wemeasured 7miRs. The primary endpoint (PE) comprised heart failure hospitalization, cardiovascu-
lar mortality, cardiac transplantation and LVAD implantation. Associations between temporal miR patterns and
the PE were investigated by joint modelling, which combines mixed models with Cox regression.
Mean age was 67± 13 years, 72% were men and 27% NYHA classes III–IV. We obtained 873 blood samples (me-
dian 3 [IQR 2–5] per patient). The PEwas reached in 41 patients (16%) during amedian follow-up of 0.9 [0.6–1.4]
years. The temporal pattern ofmiR-22-3pwas independently associatedwith the PE (HR [95% CI] per doubling of
level: 0.64 [0.47–0.77]). The instantaneous change in level (slope of the temporal miR pattern) ofmiR-22-3pwas
also independently associated with the PE (HR [95% CI] per doubling of slope: 0.33 [0.20–0.51]). These associa-
tions remained statistically signiﬁcant after adjustment for temporal patterns of NT-proBNP, Troponin T and CRP.
Conclusions: The temporal pattern of circulating miR-22-3p contains important prognostic and independent in-
formation in CHF patients. This concept warrants further investigation in larger series with extended follow-up.Erasmus M
therlands.
. This is an© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Mortality1. Introduction
Contemporary treatment of chronic heart failure ((C)HF) generally
aims to stabilize or at least decelerate disease progression. Adjustment
of pharmacotherapy is largely based on clinical judgement and thus
mostly relies on the worsening of symptoms or signs [1,2]. However,
in the context of the complexity of HF therapy, considerable clinical
skills, as well as cooperation of the patients, are required to recognize
opportunities to titrate therapies and to implement such changes inter-
vene early and timely [3]. Consequently, higher-risk patients may be
undertreated [3]. Blood biomarkers have the potential tomonitor subtleedical Centre, room
open access article underchanges in the heart that reﬂect and possibly predict adverse changes
before they become clinically apparent or reported [4]. The value of bio-
markers, such as B-type natriuretic peptides (BNP), cardiac troponins
and C-reactive protein (CRP), for risk stratiﬁcation of CHF patients has
already been demonstrated [5–8]. Moreover, natriuretic peptide-
guided HF therapy has recently been given a class IIa recommendation
in US HF guidelines to achieve guideline-directed medical therapy [2,9].
Nevertheless, the predictive capability of the aforementioned bio-
markers for worsening of CHF still leaves room for improvement.
MicroRNAs (miRs) are upcoming novel biomarkers that seem promis-
ing for early diagnosis and treatment of HF. MiRs are non-coding, ~22
nucleotide long RNA sequences, which target messenger RNAs for
cleavage or translational repression and thereby inﬂuence a great vari-
ety of biological processes [10]. The stability of miRs in plasma, and con-
sequently their reliable assessment in easily accessible samples,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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eases [11]. Studies revealing that deletion of Dicer, a gene encoding an
RNase III endonuclease essential for miR processing, leads to cardiac re-
modelling and dilation, were the ﬁrst to show involvement of miRs in
HF [12,13] and to suggest thatmiRsmight be used as biomarkers for car-
diovascular diseases [14]. Several other studies have subsequently
shown associations between miRs and myocardial infarction [15–18]
and HF [19–24]. However, most studies pertaining to HF were per-
formed in case-control settings and had a limited sample size. Further-
more, these studies usually assessed miRs only once. Repeated,
longitudinal miR assessment in CHF patients may, however, provide in-
sight into individual, temporal patterns and the patient's ensuing risk of
disease progression. The temporal patterns of miRs in patients with
known CHF have not yet been investigated.
In the current prospective, observational study, we have performed
frequent (up to 8), repeated measurements of multiple miRs that
were previously linked to HF (miR-1254, miR-22-3p, miR-423-5p,
miR-486-5p and miR-320a) or have been shown to be cardiac-
enriched (miR-345-5p, miR-378a-3p) in a cohort of 263 outpatients
with CHF, and have subsequently investigated the associations of the
obtained temporal patterns with adverse clinical outcome during
follow-up.
2. Methods
2.1. Patients
The Serial biomarker measurements and new echocardiographic techniques in chronic
heart failure patients result in tailored prediction of prognosis (Bio-SHiFT) study wasFig. 1. Inclusion and edesigned to investigate the relationship between temporal patterns of biomarkers in-
volved in CHF and prognosis. Bio-SHiFT is an ongoing prospective, observational study
of stable outpatients with CHF, conducted in Erasmus MC, Rotterdam, The Netherlands
and Medical Centre Alkmaar, The Netherlands. Patients were recruited during their regu-
lar outpatient visits andwere in clinically stable condition. Patients were eligible for inclu-
sion if aged 18 years or older, capable of understanding and signing informed consent, and
if CHF (including HFwith preserved ejection fraction (HFPEF)) was diagnosed ≥3 months
ago according to the guidelines of the European Society of Cardiology (ESC) [25–27]. De-
tailed inclusion and exclusion criteria are shown in Fig. 1. The study was approved by
the medical ethics committees of the participating hospitals and was conducted in accor-
dance with the Declaration of Helsinki. Written informed consent was obtained from all
patients.The study is registered in ClinicalTrials.gov, number NCT01851538. In the current
paper, we have performed an analysis on the 263 patients who were enrolled during the
ﬁrst inclusion period between October 2011 and June 2013. Follow-up for this analysis
lasted from October 2011 until November 2013.2.2. Baseline assessment
At baseline patients were evaluated by trained research physicians, who collected in-
formation onHF related symptoms includingNYHAclass [25,26] and performed a physical
examination, including blood pressure, heart rate and body mass index. Information on
aetiology of heart failure, presence of systolic dysfunction, cardiovascular risk factors,
medical history and medical treatment was retrieved primarily from hospital records
and was completed by anamnesis in case of ambiguities. History of myocardial infarction,
percutaneous coronary intervention (PCI), coronary artery bypass grafting, valvular heart
disease, atrial ﬁbrillation or other arrhythmias, device implantation, cerebrovascular acci-
dent, diabetes mellitus, hypercholesterolemia, hypertension, and sleep apnea were de-
ﬁned as a clinical diagnosis of these conditions, as reported by the treating physician in
the medical chart. History of chronic renal failure was deﬁned as glomerular ﬁltration
rate less than 60 mL/min/1.73 m2. Alcohol consumption was deﬁned as drinking ≥1 alco-
holic consumption per day. Electrocardiography and echocardiography were performed.
Data were entered into electronic case report forms. Non-fasting blood and urine samples
were collected.xclusion criteria.
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All patients continued routine outpatient visits during the study. Study follow-up
visits were scheduled every 3 months (a window of ±1 month was allowed), for a max-
imum of 30 months. For patients' convenience, study visits and routine outpatient visits
were combined when possible. At each tri-monthly study visit, a shortmedical evaluation
was performed and blood and urine samples were collected. Adverse cardiovascular
events and changes in medication were recorded in electronic case report forms.
2.4. Blood sampling and miR measurement
Blood samples were collected at baseline and at each follow-up visit, and were proc-
essed and stored locally at a temperature of −80 °C within 2 h after blood collection.
When applicable, samples were transported to the central laboratory (Erasmus MC, Rot-
terdam, The Netherlands) under controlled conditions (at a temperature of −80 °C),
until batch analysis took place. Accordingly, results of the biomarker assayswere not avail-
able to treating physicians at the time of the outpatient visits. Thus, the biomarker mea-
surements did not lead to treatment adjustments, and all patients received usual care
based on European guidelines [25,26].
For the purpose of the current investigation, stored plasma samples were transported
under controlled conditions to ACS Biomarker, Amsterdam, The Netherlands, and seven
miRs were measured in one batch: miR-1254, miR-22-3p, miR-345-5p, miR-378a-3p,
miR-423-5p, miR-486-5p and miR320a. MiR-1254, miR-22-3p, miR-423-5p, miR-486-5p
and miR-320a were selected because they were associated with HF in previous studies
[11,21,24]. MiR-378a-3p and miR-345-5p were selected because of their presence in
cardiomyocytes [28]. Plasma was thawed on ice and RNA isolation was performed using
the TRIZOL LS reagent (Life Technology) according to the manufacturer's protocol, with
a starting volume of 200 μl plasma. Subsequently, 8 μl of the eluate from the RNA isolation
was used for the reverse transcription reaction. The transcription followed the
manufacturer's protocol of the miScript Reverse Transcription Kit (Qiagen). For real-
time PCR, 2 μl of 10× diluted cDNA was used in a total volume of 10 μll. The real-time
PCR reaction was performed on a LightCycler 480 using the following program: 5 min of
pre-incubation at 95 °C; 10 s of denaturation at 95 °C, 20 s of annealing at 58 °C and 30 s
of elongation at 72 °C, in a total of 45 cycles. Data were analysed with LinRegPCR quanti-
tative PCR data analysis software.MiR valueswere normalized using exogenous C. elegans
miR-39 as a spike-in control, which was applied prior to the RNA isolation step. The for-
ward primers used were: miR-423-5p: TGAGGGGCAGAGAGCGAGACTTT; miR-22-3p:
AAGCTGCCAGTTGAAGAACTGT; miR-378a-3p: ACTGGACTTGGAGTCAGAAGG; miR-1254:
CTGGAAGCTGGAGCCTGC; miR-345-5p: GCTGACTCCTAGTCC; miR-486-5p: TCCTGTACT
GAGCTG; miR-320a: AAAAGCTGGGTTGAGAGGGCGA.
Batch analysis of N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitive
cardiac troponin T (HsTNT) and C-reactive protein was performed in the Clinical Chemistry
Laboratory of the Erasmus MC, Plasma NT–proBNP and cardiac Troponin T were analysed
using electrochemiluminesence immunoassays (Roche Diagnostics, Elecsys 2010,
Indianapolis, Indiana, USA), measuring concentrations ranging from 5 to 35,000 ng/l and 3
to 10,000 ng/l, respectively. CRP was measured using an immunoturbidimetric assay (Roche
Hitachi 912 chemistry analyser, Basel, Switzerland), which measures concentrations ranging
from 0.3 to 350 mg/l.
2.5. Clinical study endpoints
During follow-up, endpoints were recorded in the electronic case report forms by trained
research physicians, and associated hospital records and discharge letters were collected. A
clinical event committee blinded to the biomarker results subsequently reviewed all collected
information and adjudicated primary and secondary endpoints.
The primary endpoint comprised the composite of cardiac death, cardiac transplanta-
tion, left ventricular assist device implantation, and hospitalization for themanagement of
acute orworsenedHF. Secondary endpoints included individual components of the prima-
ry endpoint, as well as myocardial infarction, percutaneous coronary intervention, coro-
nary artery bypass grafting, cerebrovascular accident, and all-cause mortality.
Cardiac death was deﬁned as death from myocardial infarction or other ischemic
heart disease (ICD-10: I20–I25), death from other heart disease including HF (I30–I45
and I47–I52), sudden cardiac death (I46), sudden death undeﬁned (R96) or unwitnessed
or ill-described death (R98, R99). Hospitalisation for acute orworsenedHFwas deﬁned as
exacerbation of symptoms typical of HF, in combination with 2 of the following: BNP or
NT-proBNP N3× ULN, signs of worsening HF, such as pulmonary rales, raised jugular ve-
nous pressure or peripheral oedema, increased dose or intravenous administration of di-
uretics, or administration of positive inotropic agents.
2.6. Statistical analysis
Distributions of continuous variables, including biomarker and miR concentrations,
were tested for normality using the Kolmogorov-Smirnov test. Variables with normal dis-
tributions are presented as mean ± SD. Variables with non-normal distributions are pre-
sented as median and interquartile range (IQR). Categorical data are displayed as count
and percentage.
In case of skewed distributions, continuous variables were logarithmically trans-
formed for further analyses. Associations between temporal patterns of each separate
miR and the primary endpoint were assessed using a joint modelling approach, which
combines a linear mixed-effects model for the serial miR measurements with a Coxproportional hazards model for the occurrence of the primary endpoint. Results are pre-
sented as hazard ratios (HRs) per doubling of the miR concentration at any point in
time, alongwith the corresponding 95% CIs. All analyseswere adjusted for age and gender.
Subsequently, additional multivariable adjustment for potential confounding variables
wasperformed. For this purpose, associations between patient characteristics and baseline
miR levels, as well as associations between patient characteristics and the primary end-
point, were identiﬁedusing univariable linear- or Cox regression analyses, when appropri-
ate. All characteristics associated with the miRs or the primary endpoint were
subsequently used as covariates in the mixed-effects and Cox models used to construct
the jointmodels. Adjustment for repeatedly assessedNYHA classwas performed by enter-
ing NYHA class as a time-dependent variable into the joint model.
The above-described analysis assesses the predictive value of the temporal pattern of
the actual miR measurements. However, additional features of the miR's trajectory may
better predict the primary endpoint [29,30]. Therefore, we investigated whether the in-
stantaneous rate of change in miR (slope of the miR trajectory) is associated with the
risk of the primary endpoint. Furthermore, to assess the predictive value of long-term el-
evation of miR levels, we investigated the associations between the area under the miRs'
trajectory and the primary endpoint. This area can be considered as a weighted average
of the total longitudinal proﬁle of each patient. The results are presented as HRs per dou-
bling of the area at any point in time, with 95% CIs.
Subsequently, we assessedwhether the predictive value of the temporal miR patterns
was independent of temporal patterns of NT-proBNP, HsTNT and CRP. For this purpose, all
individual temporal miR patterns (of miRs signiﬁcantly associated with the primary end-
point), as well as NT-proBNP, HsTNT and CRP patterns, derived from the adjusted joint
models were saved and subsequently entered simultaneously as time-varying covariates
into an extended Cox analysis. The same approach was used to investigate the indepen-
dent predictive value of the slope and the area under the curve of the temporal miR pat-
terns associated with the primary endpoint.
To investigate the associations between repeated miR measurements and repeated
NT-proBNP, HsTNT and CRP measurements, we used generalised estimating equations.
Herewith, we examined whether the miR level at a certain time-point is associated with
the level of the other biomarkers at that same time-point.
All analyses were performed with R Statistical Software using package JM [29,30]. All
tests were two-tailed and p-values b 0.05 were considered statistically signiﬁcant.
3. Result
3.1. Baseline characteristics
From October 2011 to June 2013, 263 patients were included. Mean
age was 67 years (SD ± 13), 72% were men, and 73%were in New York
Heart Association (NYHA) class I or II (Table 1). Median baseline NT-
proBNP was 139.6 pmol/L (IQR 51.9–272.9), HsTNT 18.0 ng/l (IQR
9.6–33.2) and CRP 2.2 mg/l (IQR 0.9–4.8). Median duration of HF at in-
clusion was 4.6 years (IQR 1.7–9.9). Associations between patient char-
acteristics and baseline miR measurements are presented in the
Supplementary table. Of note is the presence of a signiﬁcant association
between ischemic cardiomyopathy (ICM) and several miRs. This is fur-
ther illustrated in Fig. 2. No signiﬁcant associations were present with
other baseline characteristics.
3.2. Clinical endpoints
The primary, composite endpoint was reached by 41 patients (16%),
during a median follow-up of 0.9 [0.6–1.4] years: 5 patients died from a
cardiovascular cause, 35 patients were re-hospitalized for worsened HF
and1patient underwent heart transplantation. Of the 35patients reaching
the primary endpoint because of re-hospitalisation forHF, 16 patients died
eventually during further follow-up, of whom12 died from a cardiovascu-
lar cause. Overall all-cause mortality was thus 21 (8.0%).
Of all baseline variables, NYHA class (HR 1.98; CI 1.24–3.16 for III/IV vs
I/II), baseline NT-proBNP (HR per two-fold difference of baseline NT-
proBNP 1.42; CI 1.09–1.86), and baseline CRP (HR per two-fold difference
of baseline CRP 1.29; CI 1.05–1.60) were independently associated with
theprimary endpoint. As shown inTable2, noneof thebaselinemiRvalues
were associated with the primary endpoint, or the secondary endpoint
comprising HF hospitalisations only.
3.3. Temporal miR patterns and the primary endpoint
During follow-up, we collected 923 blood samples, of which 885
were drawn before the occurrence of the primary endpoint (median
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in 873 of these samples. The temporal pattern of miR-22-3p was in-
versely associated with the primary endpoint (age and gender adjusted
HR per doubling of miR-22-3p level, 0.64; CI 0.47–0.77; p b 0.001), i.e.Table 1
Baseline characteristics.
Total (n = 263)
Demographics
Age 67 (±13)
Male gender 189 (72)
Caucasian ethnicity 244 (94)
Clinical characteristics
Body mass index kg/m2 28 (±5)
Heart rate, bpm 67 (±12)
Systolic blood pressure, mmHg 122 (±20)
Diastolic blood pressure, mmHg 73 (±11)
Biomarker level
NT-proBNP (pmol/L) 139.6 (51.9 – 272.9)
HsTNT (ng/l) 18.0 (9.6 – 33.2)
CRP (mg/l) 2.2 (0.9 – 4.8)
Features of heart failure
Duration of heart failure, years 4.6 (1.7 – 9.9)
NYHA class I 75 (29)
NYHA class II 115 (44)
NYHA class III or IV 69 (27)
Left ventricular function
Systolic dysfunction 250 (95)
HFPEF 13 (5)
LVEFa 32 (±10)
Etiology of heart failure
Ischemic heart disease 117 (44)
Hypertension 34 (13)
Secondary to valvular heart disease 12 (5)
Cardiomyopathy 68 (26)
Dilated 49 (19)
Hypertrophic 12 (5)
Non compaction 4 (1)
Unclassiﬁed 3 (1)
Unknown 19 (7)
Other 13 (5)
Medical history
Myocardial infarction 94 (36)
PCI 82 (31)
CABG 43 (16)
Valvular heart disease 136 (53)
Atrial ﬁbrillation 105 (40)
Other arrhythmia 82 (32)
ICD 151 (59)
CRT 78 (30)
Pacemaker 38 (15)
CVA 41 (16)
Chronic renal failure 136 (53)
Diabetes Mellitus 81 (31)
Known hypercholesterolemia 93 (35)
Hypertension 120 (46)
Sleep apnea 26 (10)
Intoxications
Alcohol consumption (N1 unit/day) 108 (42)
Smoking 185 (71)
Ever 186 (72)
Current 26 (10)
Medication use
ACE-i 173 (67)
ARB 75 (29)
Aldosteron antagonist 178 (68)
Diuretic 237 (90)
Beta-blocker 232(88)
Aspirin 45 (17)
Vitamin K antagonist 200 (77)
Nitrates 44 (17)
Digoxin 59 (23)
Antiarrhythmics 39 (15)
Fig. 2. Associations between baseline MicroRNA levels and presence of ischemic
cardiomyopathy.higher miR-22-3p was associated with lower risk of events (Table 3).
As described above, baseline measurements of several miRs were asso-
ciated with ICM. On the other hand, NYHA class was independently as-
sociated with the primary endpoint. Therefore, the baseline variables
ICM and NYHA class were added to the models. After adjustment for
age, gender, NYHA class and ICM, the association between the temporal
pattern of miR-22-3p and the primary endpoint remained present (HR
per doubling of miR-22-3p level 0.71; CI 0.44–0.94; p = 0.005). When
serial NYHA class assessmentswere added to themodel instead of base-
line NYHA assessments only, the association between miR miR-22-3p
and the primary endpoint also remained present (HR per doubling of
miR-22-3p level, 0.52; CI 0.44–0.61; p b 0.001). The temporal patterns
of the other 6 miRs were not signiﬁcantly associated with the primary
endpoint.
Baseline echocardiogramswere available in 72% of all patients due to
logistic reasons. After correction for left ventricular ejection fraction in
this subgroup, miR-22-3p remained signiﬁcantly associated with the
primary endpoint (HR per doubling of miR-22-3p level, 0.91; CI
0.85–0.95; p b 0.001).
Fig. 3 shows that in the patients who reached the endpoint, miR-22-
3p values declined as this endpoint approached, while in the patients
who did not reach the endpoint, miR-22-3p values remained stable.3.4. Slope and area under the curve of the temporal miR patterns and the
primary endpoint
The hazard ratios for the doubling of the slopes and areas under the
curve of the temporal miR patterns are displayed in Table 3. For 4 of the
miRs (miR-345-5p, miR-378a-3p, miR-423-5p, and miR-486-5p),
slopes remained virtually constant over time, and hazard ratios were
not calculable. The slope of the temporal pattern of miR-22-3p was in-
versely associatedwith the primary endpoint aftermultivariable adjust-
ment (HR per doubling of miR-22-3p slope at any given time point,
0.33; CI 0.20–0.51; p b 0.001), while the slopes of the patterns of miR-
1254 and miR-320a were not. None of the areas under the curves of
the temporal miR patterns were associated with the primary endpoint.Notes to Table 1:
Normally distributed continuous variables are presented as mean (± standard deviation).
Non-normally distributed continuous variables are expressed as median (25th–75th per-
centile). Categorical variables are expressed as count (percentage). Valid percentagesmay
vary for some counts, because ofmissing values. ACE-I= ace inhibitor; ARB=angiotensin
II receptor blocker; CABG= coronary artery bypass grafting; COPD= chronic obstructive
pulmonary disease; CRP = C-reactive protein; CRT = cardiac resynchronization therapy;
CVA= cerebrovascular accident; HFPEF = heart failure with preserved ejection fraction;
HsTNT = high sensitive cardiac troponin T; ICD= implantable cardioverter/deﬁbrillator;
LVEF= left ventricular ejection fraction; NT-proBNP=N-terminal pro-B-type natriuretic
peptide NYHA=New York heart association; PCI = percutaneous coronary intervention.
a Baseline echocardiograms were available in 72% of all patients because of logistic
reasons.
Table 2
Associations between baseline miRs and the primary endpoint and secondary endpoint.
Primary endpoint Secondary endpoint
HR⁎ (95% CI) P HR (95% CI) P
miR-1254 1.01 (0.92–1.09) 0.91 1.00 (0.91–1.09) 0.99
miR-22-3p 1.02 (0.93–1.12) 0.61 1.00 (0.90–1.09) 0.85
miR-345-5p 0.99 (0.89–1.09) 0.81 0.95 (0.86–1.06) 0.38
miR-378a-3p 1.00 (0.91–1.11) 0.93 0.99 (0.89–1.09) 0.77
miR-423-5p 1.01 (0.91–1.11) 0.92 0.97 (0.87–1.07) 0.53
miR-486-5p 1.04 (0.94–1.15) 0.47 1.00 (0.89–1.11) 0.93
miR-320a 1.04 (0.95–1.13) 0.44 1.02 (0.93–1.12) 0.71
miR =microRNA.
Primary endpoint: cardiac death, cardiac transplantation, left ventricular assist device im-
plantation, and hospitalization for the management of acute or worsened heart failure;
secondary endpoint: hospitalization for the management of acute or worsened heart
failure.
⁎ Hazard ratios (HRs) and corresponding conﬁdence intervals (CIs) were calculated
using Cox regression analyses and are given per doubling of level of miR.
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multiple-marker model
After constructing the multivariable models that corrected for age,
sex, ICM and NYHA class, we proceeded to additionally adjust the asso-
ciation between the temporal miR-22-3p pattern and the primary end-
point for temporal patterns of the other biomarkers which were
measured in this study (NT-proBNP, HsTNT andCRP).Wedid this by en-
tering the multivariably adjusted temporal pattern of miR-22-3p, as
well as the multivariably adjusted temporal patterns of NT-proBNP,
HsTNT and CRP simultaneously into one model. We found an indepen-
dent association of miR-22-3p (HR per doubling of miR-22-3p level at
any given time point, 0.61; CI 0.51–0.73; p b 0.001) with the primary
endpoint. Temporal patterns of NT-proBNP and CRP level were also in-
dependently associated with the primary endpoint in the multiple-
marker model (HRs: 1.34 (1.04–1.71) and 2.14 (1.59–2.88), respective-
ly), while the temporal pattern of HsTNT was not (HR: 1.30
(0.91–1.84)). The slope of the temporal pattern of miR-22-3p also
remained signiﬁcantly associated with the primary endpoint after ad-
justment for the slopes of the temporal patterns of NT-proBNP, Tropo-
nin T and CRP (HR per doubling of miR-22-3p slope at any given time
point, 0.55 (0.46–0.65); p b 0.001).Table 3
Associations between temporal miR patterns and the primary endpoint.
miR-1254 miR-22-3p miR-345-5p miR
HRa
(95% CI)
p HRa
(95% CI)
p HRa
(95% CI)
p HR
Temporal pattern of miR value
Adjusted for age
and gender
1.02
(0.71–1.26)
0.782 0.64
(0.47–0.77)
b0.001 1.01
(0.97–1.04)
0.624 0.8
(0.
Multivariable
adjustedb
0.97
(0.78–1.22)
0.757 0.71
(0.44–0.94)
0.005 1.00
(0.97–1.03)
0.921 0.8
(0.
Slope of temporal pattern
Adjusted for age
and gender
1.29
(0.75–2.49)
0.456 0.20
(0.09–0.50)
b0.001 NA NA NA
Multivariable
adjustedb
1.30
(0.79-2.35)
0.288 0.33
(0.20–0.51)
b0.001 NA NA NA
Area under the curve of temporal pattern
Adjusted for age
and gender
1.09
(0.97–1.27)
0.206 1.00
(0.80–1.14)
0.898 NA NA NA
Multivariable
adjustedb
1.26
(0.95–1.53)
0.100 0.99
(0.88–0.17)
0.846 NA NA NA
miR =microRNA.
a Hazard ratios (HRs) and corresponding 95% conﬁdence intervals (CIs) are given per doubl
b Adjusted for age, gender, New York Heart Association class and ischemic cardiomyopathy.3.6. Repeated miR measurements and other biomarkers
Associations between repeatedly measured miR and repeatedly
measured NT-proBNP, HsTNT and CRP, calculated using generalised es-
timating equations, are displayed in Table 4. Of note are the signiﬁcant
inverse associations between miR-345-5p and CRP (β-coefﬁcient [95%
CI]:−0.04 [−0.07 to−0.01] 10log(mg/l) per 10log increase in miR-
345-5p level; p = 0.012) and miR-22-3p and HsTNT (β-coefﬁcient
[95% CI]: −0.01 [−0.02 to −0.00] 10log(mg/l) per 10log increase in
miR-22-3p level; p=0.014; aswell as the borderline signiﬁcant inverse
association between miR-22-3p and CRP (β-coefﬁcient [95% CI]:−0.02
[−0.04–0.00] 10log (mg/l) per 10log increase in miR-22-3p level; p =
0.051). No further associations between repeatedly measured miR and
repeatedly measured NT-proBNP, HsTNT and CRP were found.4. Discussion
In this prospective, observational cohort of CHF patients, temporal
miR-22-3p patterns were inversely and independently associated with
adverse outcome. The association was independent of temporal NT-
proBNP, HsTNT and CRP patterns. The instant rate of change in miR-
22-3p level (in terms of the slope of the temporal pattern) was also in-
versely associated with adverse outcome. Moreover, we found inverse
associations of temporal patterns of miR-22-3p with temporal patterns
of HsTNT and CRP. An additional ﬁnding of this study was the signiﬁ-
cant, inverse association between ICM and miR-1254, miR486-5p and
miR-320a.
Our study has several strengths. Although the number of incident
endpoints was limited, this is the largest study to date that has exam-
ined miRs in a prospective cohort of patients with chronic HF. NT-
proBNP, HsTNT and CRP were measured concomitantly, and, in addi-
tion, frequent repeated measurements were performed during follow-
up, both of themiRs and of the established blood biomarkers. Statistical
models containing all these, repeatedly measured, biomarkers were
constructed andmodern statisticalmethodswere applied (‘jointmodel-
ling’), which take into account the continuous, dynamic changes in bio-
marker patterns and thus result in less bias than simpler analyses such
as delta's between two measurements. Herewith, the study expands
existing evidencewith regard tomiRs and cardiovascular disease in sev-
eral respects.-378a-3p miR-423-5p miR-486-5p miR-320a
a (95% CI) p HRa
(95% CI)
p HRa
(95% CI)
p HRa (95% CI) p
4
69–1.03)
0.085 1.01
(0.97–1.05)
0.800 1.00
(1.00–1.01)
0.069 0.92
(0.74–1.19)
0.516
8
71–1.06)
0.148 1.00
(0.95–1.08)
0.845 1.00
0.99–1.01)
0.380 1.01
(0.78–1.22)
0.896
NA NA NA NA NA 0.51
(0.29–0.90)
0.012
NA NA NA NA NA 0.59
(0.33–1.12)
0.102
NA NA NA NA NA 1.16
(0.94–1.42)
0.257
NA NA NA NA NA 1.19
(0.88–1.44)
0.330
ing of value, slope or area under the curve at any point in time.
Fig. 3. Temporal evolution ofmicroRNA levels. Legend: Temporal evolutionwas estimated by usingmixedmodels. Y-axis: arbitrary units [a.u.] representing relativemiRNA expression levels. X-axis: time in years as the endpoint approaches (time=0
denotes the moment that the endpoint occurs for the patients reaching the endpoint, and the moment of right-censoring for the patients not reaching the endpoint). Red solid line: miR expression level in patients reaching the endpoint. Red dotted
lines: 95% conﬁdence interval. Black solid line: miR expression level in patients not reaching the endpoint. Black dotted line: 95% conﬁdence interval.
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Table 4
Associations between repeatedly measured miRs and B-type natriuretic peptide, high sensitive cardiac troponin T and C- reactive protein.
NT-proBNP HsTNT CRP
Beta coefﬁcient (95% CI) P Beta coefﬁcient (95% CI) P Beta coefﬁcient (95% CI) P
miR-1254 0.07 (−0.05–0.02) 0.27 0.00 (−0.01–0.01) 0.59 0.00 (−0.02–0.02) 0.92
miR-22-3p −0.01 (−0.022 to−0.00) 0.14 −0.01 (−0.02 to−0.00) 0.014 −0.03 (−0.06–0.00) 0.051
miR-345-5p −0.04 (−0.02–0.01) 0.57 −0.01 (−0.02–0.01) 0.35 −0.04 (−0.07 to−0.01) 0.012
miR-378a-3p −0.01 (−0.02–0.00) 0.12 0.00 (−0.01–0.01) 0.91 −0.02 (−0.04–0.01) 0.27
miR-423-5p 0.00 (−0.02–0.01) 0.81 −0.01 (−0.02–0.00) 0.17 −0.01 (−0.04–0.03) 0.63
miR-486-5p −0.01 (−0.02–0.01) 0.43 −0.01 (−0.02–0.01) 0.37 −0.03 (−0.06–0.00) 0.070
miR-320a 0.00 (−0.01–0.02) 0.69 0.00 (−0.01–0.01) 0.74 0.01 (−0.02–0.03) 0.71
Beta coefﬁcients and corresponding 95% conﬁdence intervals (CIs) were calculated using generalised estimating equationswith 10log transformedmicroRNAs (miRs) as independent var-
iables and 10log transformed N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitive cardiac troponin T (HsTNT) and C-reactive protein (CRP) as dependent variables.
130 N. van Boven et al. / International Journal of Cardiology 235 (2017) 124–132MiR-22-3p has previously received attention in the cancer ﬁeld; it
has been implicated in the regulation of various cellular processes, in-
cluding cell growth, apoptosis, motility, and the cell cycle [31]. With re-
gard to cardiovascular disease, fundamental experiments have
demonstrated that expression ofmiR-22-3p is enriched in striatedmus-
cle tissues (i.e. cardiac and skeletal muscles); andmiR-22-3p is thought
to be required for normal cardiac remodelling in response to stresses
[32]. A recent study in miR-22 deﬁcient mice demonstrated that miR-
22 depleted hearts quickly progress to adverse cardiac remodelling
and develop cardiac dilation,with increased cardiomyocyte loss and de-
position of ﬁbrotic tissue, and signs of heart failure [33]. Another study
also found that mice withoutmiR-22 develop dilatation of myocardium
more quickly [34]. Interestingly, several animalmodels have shown that
miR-22 may potentially serve as a therapeutic target in cardiac hyper-
trophy [33]. Recently, Gupta et al found that pharmacological inhibition
of miR-22 post-infarction activated cardiac autophagy, led to improved
cardiac function, and inhibited cardiac remodelling in older mice [35].
They also found that circulating miR-22 provides prognostic informa-
tion in HF patients. Speciﬁcally, they demonstrated an association be-
tween higher baseline levels of circulating miR-22 and mortality in154
HF patients. Repeated measurements were not performed. In the pres-
ent study, although we saw a temporal decline of miR-22-3p levels in
patients with adverse clinical outcome, we could not demonstrate a sig-
niﬁcant association between higher baseline miR-22-3p and clinical
outcome. The shorter follow-up duration of our study (median of
approx. 1 year, versus 3 years follow-up in the study of Gupta et al)
may have contributed to this. Furthermore, in an earlier study, Goren
et al, demonstrated that elevated serum levels ofmiR-22-3p identify pa-
tients with systolic heart failure using 30 stable chronic systolic heart
failure patients and 30 controls [24]. This seeming discrepancy with
our study could possibly be explained by differences in study design.
While Goren et al focused on diagnostic properties of miR-22-3p by
comparing cases and controls, we focused on prognostic value of miR-
22-3p in patients with established CHF. To the best of our knowledge,
other cardiovascular studies on miR-22-3p in human subjects are lack-
ing. Altogether, our study is in line with previous fundamental experi-
ments which demonstrated that loss of miR-22-3p leads to dilatation
of myocardium and progressive HF. Our study conﬁrms that lower
levels of miR-22-3p are associated with worsening of CHF, and that
miR-22-3p may complement established HF biomarkers in
prognostication.
Previously, several studies using animal models have shown de-
creased levels of miR-378a-3p during cardiac remodelling [36] and in
HF due to cardiac hypertrophy [37–39]. Furthermore, a signiﬁcant
down-regulation of miR-378a-3p in hearts with dilated cardiomyopa-
thy compared to non-failing control hearts has been observed [23].
Since the presence of miR-378a-3p is required to resist ventricular re-
modelling during cardiac stress, it may offer therapeutic potential for
the management of HF [38]. It has been suggested, that up-regulation
of miR-378a-3p could serve as a potential novel treatment for apoptosis
and ischemic heart disease, since up-regulation of this miR enhancedcell viability, and inhibited apoptosis and necrosis in myocardium of
rats [40]. In the current study, we also observed a tendency towards
an inverse association between the temporal pattern of miR378a-3p
and the primary endpoint in univariable models. These results concur
with the aforementioned studies.
Another miR that has previously been associated with HF, is miR-
423-5p [19,21,22,24]. However, in our study, there was no association
between the temporal pattern of miR-423-5p and the primary end-
point. Existing studies on miR-423-5p in humans all compared single
measurements in (C)HF patients with measurements in healthy con-
trols, and imply that this miR has diagnostic value for HF [19,21,24].
We did not evaluate the diagnostic value of miRs, but the prognostic
value of serial miR measurements in patients with known CHF. Al-
thoughmiR-423-5pmay discriminate between HF patients and healthy
controls, itmay lack prognostic value in patientswith longstanding CHF.
Earlier ﬁndings support this hypothesis [20]. Bauters et al. serially mea-
sured serum levels of circulatingmiR-423-5p in 246 patients with a ﬁrst
anterior Q-wave myocardial infarction, at discharge and subsequently
at 3 months and 1 year. They found no association between miR-423-
5p levels and indices of left ventricular function and left ventricular re-
modelling, whichwere serially assessed during a 1 year period after the
index myocardial infarction, nor with B-type natriuretic peptide. They
concluded that miR-423-5p is not a useful biomarker of left ventricular
remodelling after myocardial infarction [20].
The selection of the miRs for the current investigation was based on
previous studies, which used animalmodels and relatively small patient
groups. Some of these studies have shown associations between miR-
1254, miR-345-5p, miR-486-5p and miR-320a and heart failure [19,21,
24,41,42]. Again, these were mostly studies that compared HF patients
to healthy controls. In our study, we did not ﬁnd any associations be-
tween these miRs and poor outcome in CHF. Multiple other miRs, such
as miR-133a [43], have previously been associated with HF [44]. Serial
measurements of these other miRs, which were not investigated in
this study, warrant further investigation. This could lead to further im-
provements in CHF prognostication, as well as tailored adjustment of
treatment.
Some aspects of this studywarrant consideration. For the current in-
vestigationwe only used theﬁrst round of inclusions of the ongoingBio-
SHiFT study (n= 263). It should be noted that the full Bio-SHiFT cohort
is designed to have sufﬁcient statistical power to enable correction for
multiple testing in case of application of modern, large-scale biomarker
measurement methods. However, the current investigation examines
only 7 miRs, which were chosen based on pathophysiological consider-
ations. Thus, the current investigation was hypothesis-driven and not
data-driven, rendering correction for multiple testing unnecessary in
this particular case. Furthermore, with an average follow-up ~1 year,
the number of primary endpoints in the current investigation (n =
41) was limited, and consequently so was the number of covariables
that could be entered into the models. The lack of a replication popula-
tion is another limitation of the study. Finally, themajority of the patient
populationwas inNYHA functional class I or II, and thus at relatively low
131N. van Boven et al. / International Journal of Cardiology 235 (2017) 124–132risk. Accordingly, the primary outcome was predominantly composed
of heart failure hospitalizations. This may have hampered the prognos-
tic information of the other miRs tested in this study. Future studies
using high-risk patient populations should therefore re-investigate the
prognostic information carried by repeated assessment of these miRs.
Remarkably, in the present study, the rate of HFPEF was very low
compared to other epidemiological studies. This can most likely be at-
tributed to the fact that in the Netherlands, most HFPEF patients are
treated by the general practitioner or in secondary referral centres,
while the current study was performed in two centres which were
both tertiary referral centres. Potential inclusion bias is not a likely rea-
son for the low HPEF rate, because consecutive patients were screened
in both participating centres. Moreover, the number of patients on vita-
min K antagonists was quite high in this study, most likely due to the
high number of patients with left ventricular aneurysms and thrombi,
as well as the high number of patients with atrial ﬁbrillation.
In conclusion, in patients with stable CHF, the temporal pattern of
circulatingmiR-22-3p is a strong and independent predictor of progno-
sis. Thus, the use of individual patterns of change of circulating miR-22-
3p for CHF prognostication, as well as for tailored adjustment of treat-
ment, warrants further investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2017.02.078.
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